IRIS
TENTORI, LUCIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 48.565
EU - Europa 4.456
AS - Asia 760
SA - Sud America 20
Continente sconosciuto - Info sul continente non disponibili 8
AF - Africa 7
OC - Oceania 1
Totale 53.817
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.519
IT - Italia 1.267
UA - Ucraina 729
DE - Germania 655
CN - Cina 509
IE - Irlanda 426
FR - Francia 413
SE - Svezia 255
PL - Polonia 223
GB - Regno Unito 171
FI - Finlandia 149
KR - Corea 140
RU - Federazione Russa 76
CA - Canada 34
JP - Giappone 34
IN - India 28
NL - Olanda 27
CZ - Repubblica Ceca 21
BE - Belgio 15
MX - Messico 11
BR - Brasile 9
IR - Iran 9
EU - Europa 8
IL - Israele 8
CH - Svizzera 6
ES - Italia 6
VN - Vietnam 6
CL - Cile 5
HK - Hong Kong 5
CO - Colombia 4
EG - Egitto 4
KG - Kirghizistan 4
MK - Macedonia 4
AT - Austria 3
BG - Bulgaria 3
ID - Indonesia 3
PH - Filippine 3
TW - Taiwan 3
DK - Danimarca 2
MW - Malawi 2
SG - Singapore 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
BD - Bangladesh 1
CY - Cipro 1
GE - Georgia 1
JM - Giamaica 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
NO - Norvegia 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
TR - Turchia 1
Totale 53.817
Salva come PNG Salva come JPEG
Città #
Woodbridge 15.641
Wilmington 12.698
Houston 12.633
Ann Arbor 1.419
Fairfield 1.117
Jacksonville 662
Chandler 639
Ashburn 614
Seattle 438
Dublin 401
Cambridge 376
Medford 312
New York 243
Rome 236
Dearborn 228
Beijing 224
Kraków 216
Lawrence 150
Mülheim 113
Milan 112
Menlo Park 67
Zhengzhou 65
San Diego 59
Mountain View 42
Boardman 36
Redwood City 35
Falls Church 33
Civitavecchia 32
Guangzhou 32
San Mateo 28
Palo Alto 26
University Park 26
Nanjing 23
Prague 21
Hefei 20
Norwalk 19
Shanghai 19
Verona 18
Ottawa 17
Turin 16
London 15
Brussels 14
Palermo 14
Saint Petersburg 14
Kunming 13
Toronto 13
Kansas City 12
Nanchang 12
Napoli 12
Phoenix 12
Bari 11
Catania 11
Indiana 11
Naples 11
Torino 11
Florence 10
Pune 10
Chicago 9
Helsinki 9
Jinan 9
Pisa 9
Bologna 8
Brescia 8
Fuzhou 7
Minervino Murge 7
Pioppi 7
Siena 7
Detroit 6
Engelhard 6
Hebei 6
Pavia 6
Udine 6
Auburn Hills 5
Casalnuovo di Napoli 5
Kilburn 5
Nürnberg 5
Pordenone 5
San Francisco 5
Somma Lombardo 5
Ancona 4
Athens 4
Cadeo 4
Cairo 4
Calusco d'Adda 4
Changsha 4
Chengdu 4
Cittaducale 4
Cremona 4
Dong Ket 4
Hyderabad 4
Los Angeles 4
Mistretta 4
Novara 4
Palazzolo sull'Oglio 4
Redmond 4
Rubano 4
Seoul 4
São Paulo 4
Tappahannock 4
Tehran 4
Totale 49.541
Salva come PNG Salva come JPEG
Nome #
Gli inibitori della poli (ADP-ribosio) polimerasi (PARP) per superare la chemioresistenza a metilanti e inibitori di topoisomerasi I 979
L’attività fisica come terapia complementare: l’esempio delle malattie oncologiche 619
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells 467
Targeted therapy for brain tumours: role of PARP inhibitors 459
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells 441
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells 435
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1 435
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 431
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity 428
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? 428
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma 421
Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity 420
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site 418
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes 414
Challenging resistance mechanisms to therapies for metastatic melanoma 413
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds 412
Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL) 411
Una medicina che cambia: l’approccio all’ipercolesterolemia. 411
Exploiting Microglial Functions for the Treatment of Glioblastoma 409
Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of αvβ5 integrin. 408
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib 407
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. 406
Chemical xenogenization: antigenic changes of cancer cells induced by triazene compounds 406
Immunopharmacology of antitumor agents. 406
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes 405
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine 405
Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth 405
null 404
Effects of diheptyldiselenide (DDS) on human tumor cell lines and on peripheral blood mononuclear cells 402
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components 400
Thymic selection of the T-cell repertoire 400
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: Influence of 3'-azido-3'-deoxythymidine 400
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 399
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. 398
Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy 397
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines 396
A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells 396
Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin 395
Pharmacological strategies to increase the antitumor activity of methylating agents 394
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors 393
Chemotherapy in hairy cell leukemia. Preliminary results of a nonaggressive regimen 392
Drug-mediated increase of susceptibility of human lung cancer to NK or LAK effector cells 392
Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy 390
Differentiation of Ia-reactive CD8+ murine T cells does not require Ia engagement. Implications for the role of CD4 and CD8 accessory molecules in T cell differentiation 390
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor 384
Novel Glutathione S-Transferase Inhibitor Enhances Temozolomide Efficacy Against Malignant Melanoma 52nd Annual Meeting of the Italian Cancer Society. Lost in translation: bridging the gap between cancer research and effective therapies 384
Primary cultures of microglial cells for testing toxicity of anticancer drugs. 382
IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3' dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vitro 382
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 382
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 381
Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen 378
Monoclonal antibodies to CTLA-4 with focus on ipilimumab 378
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine. 377
Role of DNA repair pathways in the control of common fragile sites expression. 377
Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. 376
Induction of apoptosis in thymocytes by prostaglandin E2 in vivo 374
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. 373
Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells 372
Doping and Cancer 372
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer 372
Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma 372
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic coils to apoptosis induced by temozolomide 371
VEGFR-1 derived peptide specifically inhibits PlGF and VEGF-B-induced migration of endothelial cells and in vivo angiogenesis. 368
Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3 368
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. 367
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy 366
DNA damaging agents can induce celll cycle arrest in different phases of mitosis 366
null 366
Inhibition of metastasis induced by triazene derivatives in mice bearing Lewis Lung Carcinoma (3LL): role of protein kinase C 365
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma 363
Acquired hemoglobin H disease in a case of refractory anemia with excess of blasts (RAEB) evolving into acute nonlymphoid leukemia 362
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells 362
New aspects of immune responses against mycobacteria: immunopharmacology studies 361
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. 360
Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells 359
Pharmacological inhibition of poly (ADP-ribose) polymerase (PARP) activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells and increases temozolomide sensitivity of PARP-1 silenced melanoma cells. 357
Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester 355
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. 355
Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant 354
Systemic administration of the PARP inhibitor GPI 15427 increases the anti-tumor activity of temozolomide in melanoma, glioma and lymphoma preclinical models in vivo 353
Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. 353
Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro 353
Influenza di farmaci antivirali o antimicobatterici sulla proliferazione di monociti umani e sulla espressione del CD1b. Secondo Progetto di ricerca Tubercolosi 352
PARP inhibitors for cancer treatment: an update on current clinical trials. 350
In vitro antitumor activity of 3'-desamino-3'(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds 350
Temozolomide reduces the metastatic potential of Lewis-lung-carcinoma (3ll) in mice: role of alpha-6 integrin phosphorylation 349
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 349
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan against colon carcinomas 349
Oral administration of poly(ADP-ribose) polymerase inhibitor prevents intestinal damage induced by irinotecan and enhances the efficacy of irinotecan and temozolomide combination against colon carcinoma. 347
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan and temozolomide combination against colon carcinoma 347
PARP-1 inhibitor: a novel approach to enhance efficacy of chemotherapy. 346
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. 346
Inhibition of poly(ADP-ribose) polymerase (PARP) increases the therapeutic efficacy of the G-quadruplex ligand RHPS4/irinotecan combination in colon cancer xenografts 345
Primary cultures of microglial cells for testing toxicity of anticancer drugs 344
In vivo anti-angiogenic potential of a peptide that inhibits VEGFR-1 homodimerization and PlGF-induced migration of endothelial cells. 344
Chemopotentiation by PARP inhibitors in cancer therapy 343
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding 343
Inhibition of DNA repair enzyme potentiates apoptosis induced by temozolomide 342
PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. 342
Apoptotic and clastogenic effects of methylating agents, alone or combined with poly(ADP-ribose) polymerase inhibitor, in peripheral blood lymphocytes 341
Totale 39.066
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.039
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.039
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194.283 0 0 0 0 0 0 0 0 0 1.315 1.515 1.453
2019/202014.180 1.326 1.143 956 1.370 1.243 1.461 1.199 1.280 1.297 1.070 878 957
2020/20218.251 968 974 835 1.069 851 961 966 793 209 170 345 110
2021/20221.494 64 214 110 66 32 110 95 68 106 107 76 446
2022/20231.954 204 109 61 275 119 437 164 101 183 41 177 83
2023/2024971 101 37 83 67 110 344 86 60 47 36 0 0
Totale 54.041